U.S. tariffs on imported medicines went from a threat to policy over about eight months. In an August 5, 2025, CNBC interview, President Donald Trump said the United States would start with a "small tariff" on pharmaceutical imports, raise it to 150% within 18 months and eventually to 250%, to push drug production into the country (Reuters via BNN Bloomberg). Earlier that summer he had floated 200% (The Fiscal Times).
The September 2025 announcement
On September 25, 2025, the President announced on social media a 100% tariff on branded or patented drugs starting October 1, unless the manufacturer was building a U.S. plant (Foley Hoag). That tariff was not put into effect at the time; the administration instead negotiated company-by-company deals on pricing and U.S. manufacturing (Ropes & Gray).
The April 2026 Section 232 proclamation
On April 2, 2026, after a national-security investigation the Commerce Department opened in April 2025, the President signed a proclamation imposing 100% tariffs on patented pharmaceuticals and their key ingredients. They took effect July 31, 2026, for 17 large drugmakers named in the proclamation, most of which were exempt because of agreements with the administration (Arnold & Porter).
- Not covered: generic drugs and biosimilars, and U.S.-made products (Covington).
- Exempt: companies with "most favored nation" drug-pricing deals, or negotiating them, through January 20, 2029 (EY).
- Since September 29, 2026: the tariffs apply to branded drugmakers beyond the first 17, though exemptions, trade-deal rates and pricing deals still decide who pays and how much (Managed Healthcare Executive).
What it means for patients and hospitals
Because generics are excluded, the direct effect falls on imported brand-name drugs whose makers lack an exemption. A benefits consultant quoted by Managed Healthcare Executive did not expect a cost impact for the 2026–27 plan year, but open questions, such as how ingredients and biosimilars are treated, could change costs later.
What to watch
The proclamation lets the President revise rates or the list of covered products depending on negotiations with trading partners, and a joint status report on those talks was due by July 1, 2026 (Thompson Hine). Expect the rules to keep changing.
For residents and students, the practical effects show up in formularies, prior authorizations and the price of brand-name drugs without a generic. It is worth knowing which of your patients' medicines are imported brand-name products.
Related: White House presses 17 drugmakers on Medicaid prices and CMS awards the final Section 126 residency slots.
This article is news and education, not medical or legal advice.

